ClinicalTrials.gg
CompletedNCT05720364Updated Jun 28, 2023

Study to Evaluate the Food Effect of TP-05 in Healthy Participants

A Phase 1 interventional study of TP-05 (lotilaner oral), fasted group and TP-05 (lotilaner oral), high-fat group in Healthy, sponsored by Tarsus Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-28.

Sponsored by Tarsus Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Study summary

A Phase 1, Open-Label, Randomized, Single-Dose, Parallel-Group Study to Evaluate the Food Effect on the Pharmacokinetics of TP-05 under Fed and Fasted Conditions in Healthy Participants.

Read the detailed description

This is a Phase 1, open-label, randomized, single-dose, parallel-group study to evaluate the food effect on the pharmacokinetics of TP-05 under fed and fasted conditions in healthy participants.

The study will consist of a screening period of up to 28 days. Participants who are eligible for the study will check into the clinical research site on Day -1. All participants will undergo an overnight fast of at least 10.5 hours prior to dosing. On Day -1 participants will be randomized to receive one of three treatment regimens on Day 1: single dose of TP-05, fasted; single dose of TP-05 following a high-fat breakfast; or single dose of TP-05 following a low-fat breakfast.

Participants will be resident at the clinical research site from Day -1 until completion of assessments at 96 hours post-dose (Day 5) and return on Day 60 for a follow-up visit. Participants will complete a telephone safety follow-up visit at Day 120.

Safety will be assessed by adverse events, vital signs, performing physical examinations, electrocardiograms, and evaluating clinical laboratory results.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Tarsus Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history and physical examination
  • Participants who are non- or ex-smokers
  • No disease captuired in medical history or evidence of clinically significant findings on the physical examination and/or at Screening and Day -1, as determined by the Investigator
  • 18.5-29.9 kg/m2 (inclusive) and weighs at least 50.0 kg at Screening
  • Ability to comply with requirements

Exclusion criteria

Exclusion Criteria:

  • Female who is breast-feeding or pregnancy according to the serum pregnancy test at Screening and urine pregnancy test at Day -1 prior to study drug administration
  • History of significant to lotilaner or any related products
  • History of significant gastrointestinal, metabolic, liver, or kidney disease, or surgery that may affect drug bioavailability
  • History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease
  • History of (or active malignancy), with the exception of treated basal cell or squamous cell carcinoma
  • Positive test results for -1/HIV-2 antigen/antibody, surface antigen (HBsAg) or virus antibody (HCVAb)
  • Positive result for SARS-CoV-2 testing at Day -1
  • Use of any non-prescription or prescription drugs in the 7 days or 5 half-lives (whichever is longer) prior to study drug administration and through the treatment period of the study
  • Treatment with an drug within 30 days or 5 times the half-life (whichever is longer) prior to Screening and through Day 60 of the study
  • History of within 4 weeks prior to study drug administration or requirement to receive these vaccinations through Day 60 of the study
  • Plasma donation within 7 days prior to Screening through Day 60 of the study
  • Blood donation or significant blood loss approximately 500 mL within 56 days prior to Screening through Day 60 of the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    TP-05, Fasted Group

    Single dose of TP-05 (lotilaner oral), fasted

    Drug: TP-05 (lotilaner oral), fasted group

  • Experimental
    TP-05, High-Fat Group

    Single dose of TP-05 (lotilaner oral) following a high-fat meal

    Drug: TP-05 (lotilaner oral), high-fat group

  • Experimental
    TP-05, Low-Fat Group

    Single dose of TP-05 (lotilaner oral) following a low-fat meal

    Drug: TP-05 (lotilaner oral), low-fat group

Interventions

  • DrugTP-05 (lotilaner oral), fasted group

    TP-05 (lotilaner oral), fasted group

    Also known as: TP-05, fasted

  • DrugTP-05 (lotilaner oral), high-fat group

    TP-05 (lotilaner oral), high-fat group

    Also known as: TP-05, high-fat meal

  • DrugTP-05 (lotilaner oral), low-fat group

    TP-05 (lotilaner oral), low-fat group

    Also known as: TP-05, low-fat meal

06

What researchers measure

Primary outcomes

  1. Concentration of TP-05 in whole blood

    PK parameters for whole blood sampling methods following dose administration with a high-fat meal, low-fat meal, and fasting will be evaluated. Parameter includes concentration level.

    Time frame: Up to Day 60

  2. Exposure and PK of lotilaner in whole blood (AUC0-96hours)

    PK parameters for whole blood sampling methods following dose administration with a high-fat meal, low-fat meal, and fasting will be evaluated. Parameter includes AUC0-96hours.

    Time frame: Up to Day 5

  3. Exposure and PK of lotilaner in whole blood (Cmax)

    PK parameters for whole blood sampling methods following dose administration with a high-fat meal, low-fat meal, and fasting will be evaluated. Parameter includes Cmax.

    Time frame: Up to Day 60

  4. Exposure and PK of lotilaner in whole blood (Tmax)

    PK parameters for whole blood sampling methods following dose administration with a high-fat meal, low-fat meal, and fasting will be evaluated. Parameter includes Tmax.

    Time frame: Up to Day 60

  5. Exposure and PK of lotilaner in whole blood (Tlag)

    PK parameters for whole blood sampling methods following dose administration with a high-fat meal, low-fat meal, and fasting will be evaluated. Parameter includes Tlag.

    Time frame: Up to Day 60

Secondary outcomes

  1. Incidence of treatment emergent adverse events (TEAEs)

    Evaluate the safety of TP-05 through the incidence rate of TEAEs

    Time frame: Up to Day 120

  2. Clinically significant changes from Baseline chemistry laboratory tests

    Evaluate the safety of TP-05 through clinically significant changes from Baseline chemistry laboratory tests

    Time frame: Up to Day 60

  3. Clinically significant changes from Baseline physical examination

    Evaluate the safety of TP-05 through clinically significant changes from Baseline physical examinations

    Time frame: Up to Day 60

  4. Clinically significant changes from Baseline vital signs

    Evaluate the safety of TP-05 through clinically significant changes from Baseline vital signs

    Time frame: Up to Day 60

  5. Clinically significant changes from Baseline electrocardiograms (ECGs)

    Evaluate the safety of TP-05 through clinically significant changes from Baseline ECGs

    Time frame: Up to Day 60

07

Study locations

1 site
  • Dr. Vince Clinical Research
    Overland Park, Kansas 66212, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in May 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2023
First posted
Feb 9, 2023
StartActual
Jan 19, 2023
Primary completionActual
May 30, 2023
CompletionActual
May 30, 2023
Last update
Jun 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05720364
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Feb 9, 2023
Start date
Jan 19, 2023
Primary completion
May 30, 2023
Completion
May 30, 2023
Last update
Jun 28, 2023

Study contacts

Jose Trevejo, MD, PhD
study director · Tarsus Pharmaceuticals, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion